TELA Bio (TELA) Expected to Release Quarterly Earnings on Monday

TELA Bio (NASDAQ:TELA) is expected to be releasing its Q2 2026 results after the market closes on Monday, August 10th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $20.0080 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:30 PM ET.

TELA Bio (NASDAQ:TELA) last released its earnings results on Tuesday, May 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07). TELA Bio had a negative net margin of 49.30% and a negative return on equity of 1,320.81%. The business had revenue of $19.06 million during the quarter, compared to the consensus estimate of $18.60 million. On average, analysts expect TELA Bio to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

TELA Bio Stock Up 2.1%

Shares of TELA stock opened at $0.72 on Monday. The firm’s fifty day moving average price is $0.80 and its two-hundred day moving average price is $0.81. The company has a current ratio of 3.61, a quick ratio of 2.92 and a debt-to-equity ratio of 8.82. TELA Bio has a 1 year low of $0.50 and a 1 year high of $2.14. The firm has a market capitalization of $32.46 million, a P/E ratio of -0.92 and a beta of 1.34.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of TELA Bio in a research report on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $2.20.

Hedge Funds Weigh In On TELA Bio

Hedge funds have recently bought and sold shares of the business. XTX Topco Ltd bought a new stake in TELA Bio in the 4th quarter valued at about $48,000. Renaissance Technologies LLC boosted its stake in shares of TELA Bio by 101.4% in the fourth quarter. Renaissance Technologies LLC now owns 128,700 shares of the company’s stock valued at $152,000 after buying an additional 64,800 shares during the period. Susquehanna International Group LLP boosted its stake in shares of TELA Bio by 551.2% in the third quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock valued at $128,000 after buying an additional 72,594 shares during the period. Finally, Citadel Advisors LLC grew its position in TELA Bio by 161.3% during the third quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock worth $53,000 after buying an additional 21,781 shares in the last quarter. 94.35% of the stock is owned by institutional investors.

About TELA Bio

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.